Navigation Links
A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
Date:5/1/2013

BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with treatment-resistant depression (TRD)*, according to insights from surveyed psychiatrists in the United States and Europe as well as U.S. managed care organizations' (MCOs') pharmacy directors. Pharmacological treatment for TRD most typically involves switching, combining (two antidepressants from different classes) or augmenting (combining another agent with an antidepressant). The atypical antipsychotics Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole) and Seroquel XR (AstraZeneca's quetiapine XR, generics in the United Kingdom and Germany) are two therapies approved as adjunct therapies to antidepressants in the U.S. and are also used in this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO

"Adjunctive treatment with atypical antipsychotics, though considered effective by thought-leaders, generally results in significant weight gain, and so emerging therapies could differentiate themselves in the marketplace by demonstrating both efficacy in TRD and by having a more tolerable weight gain profile," said Decision Resources Analyst Alana Simorellis , Ph.D.

The DecisionBase 2013 report entitled In the Crowded Antidepressant Market Space, What Are the Remaining Opportunities for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. This finding suggests that cost-sensitive payers consider efficacy improvements to be of greater value than improvements in tolerability.

Surveyed U.S. psychiatrists expect to prescribe Eli Lilly's emerging therapy edivoxetine to 25 percent of their patients with TRD. Decision Resources forecasts that edivoxetine will earn a U.S. patient share for TRD similar to surveyed psychiatrists' estimate by 2021, based on top-line results from Phase II/III trials of edivoxetine as an adjunct therapy to SSRIs and positive Phase II/III monotherapy results in patients with major depressive disorder.

Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies profiled in the report, Eli Lilly's edivoxetine shows considerable promise as an adjunct to antidepressant therapy. Additionally, edivoxetine appears to offer a more favorable profile in terms of neurological side effects and risk of weight-gain relative to the atypical antipsychotics.

*The majority of physicians interviewed and surveyed by Decision Resources consider a patient "treatment-resistant" if depressive symptoms persist despite treatment with at least two different trials of antidepressant drugs from two different drug classes.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 

 

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
2. Cancer drug shortages mean higher costs and greater risk for patients
3. New Report Details NCPA Efforts to Drive Greater Medication Adherence
4. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
5. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
6. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
7. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
8. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
9. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):